RXRX PE Ratio & Valuation, Is RXRX Overvalued

Historical Valuation

Recursion Pharmaceuticals Inc (RXRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 27.49 is considered Undervalued compared with the five-year average of -7.39. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between 795.67 to 796.54 according to relative valuation method. Compared to the current price of 3.45 USD , Recursion Pharmaceuticals Inc By Undervalued By 99.57%.

Relative Value

Fair Zone

795.67-796.54

Current Price：3.45

99.57%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Recursion Pharmaceuticals Inc (RXRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Recursion Pharmaceuticals Inc (RXRX) has a current Price-to-Book (P/B) ratio of 1.97. Compared to its 3-year average P/B ratio of 3.54, the current P/B ratio is approximately -44.34% higher. Relative to its 5-year average P/B ratio of 3.55, the current P/B ratio is about -44.41% higher. Recursion Pharmaceuticals Inc (RXRX) has a Forward Free Cash Flow (FCF) yield of approximately -20.48%. Compared to its 3-year average FCF yield of -16.76%, the current FCF yield is approximately 22.17% lower. Relative to its 5-year average FCF yield of -12.43%, the current FCF yield is about 64.79% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RXRX competitors is 27483.40, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX.O) exhibits a P/S ratio of 27.49, which is -99.9% above the industry average. Given its robust revenue growth of 681.74%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RXRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RXRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RXRX currently overvalued or undervalued?

Recursion Pharmaceuticals Inc (RXRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 27.49 is considered Undervalued compared with the five-year average of -7.39. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between 795.67 to 796.54 according to relative valuation method. Compared to the current price of 3.45 USD, Recursion Pharmaceuticals Inc is Undervalued By 99.57%.

What is Recursion Pharmaceuticals Inc (RXRX) fair value?

RXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Recursion Pharmaceuticals Inc (RXRX) is between 795.67 to 796.54 according to relative valuation method.

How does RXRX's valuation metrics compare to the industry average?

The average P/S ratio for RXRX's competitors is 27483.40, providing a benchmark for relative valuation. Recursion Pharmaceuticals Inc Corp (RXRX) exhibits a P/S ratio of 27.49, which is -99.90% above the industry average. Given its robust revenue growth of 681.74%, this premium appears sustainable.

What is the current P/B ratio for Recursion Pharmaceuticals Inc (RXRX) as of Mar 12 2026?

As of Mar 12 2026, Recursion Pharmaceuticals Inc (RXRX) has a P/B ratio of 1.97. This indicates that the market values RXRX at 1.97 times its book value.

What is the current FCF Yield for Recursion Pharmaceuticals Inc (RXRX) as of Mar 12 2026?

As of Mar 12 2026, Recursion Pharmaceuticals Inc (RXRX) has a FCF Yield of -20.48%. This means that for every dollar of Recursion Pharmaceuticals Inc's market capitalization, the company generates -20.48 cents in free cash flow.

What is the current Forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX) as of Mar 12 2026?

As of Mar 12 2026, Recursion Pharmaceuticals Inc (RXRX) has a Forward P/E ratio of -3.38. This means the market is willing to pay $-3.38 for every dollar of Recursion Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Recursion Pharmaceuticals Inc (RXRX) as of Mar 12 2026?

As of Mar 12 2026, Recursion Pharmaceuticals Inc (RXRX) has a Forward P/S ratio of 27.49. This means the market is valuing RXRX at $27.49 for every dollar of expected revenue over the next 12 months.

RXRX Valuation